



Louisiana

mecamylamine (Vecamyl®)

Policy # 00528

Original Effective Date: 01/01/2017

Current Effective Date: 10/12/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider mecamylamine (Vecamyl®)‡ for the treatment of essential hypertension and in uncomplicated cases of malignant hypertension to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for mecamylamine (Vecamyl) will be considered when the following criteria are met:

- Patient has a diagnosis of moderately severe to severe essential hypertension OR an uncomplicated case of malignant hypertension; AND
- Patient has tried and failed (e.g. intolerance or inadequate response) at least THREE other antihypertensive agents, unless there is clinical evidence or patient history that suggests the use of THREE other antihypertensive agents will be ineffective or cause an adverse reaction to the patient.

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of mecamylamine (Vecamyl) WITHOUT evidence that the patient has tried and failed at least THREE other antihypertensive agents to be **not medically necessary.****

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

mecamylamine (Vecamyl®)

Policy # 00528

Original Effective Date: 01/01/2017

Current Effective Date: 10/12/2020

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of mecamylamine (Vecamyl) for any indication other than its respective FDA approved indication to be **investigational**.*

Background/Overview

Vecamyl is approved for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Vecamyl is supplied as 2.5 mg tablets. Vecamyl inhibits acetylcholine at the autonomic ganglia, causing a decrease in blood pressure. Typically, by the point of disease progression where Vecamyl would be warranted, a patient would have tried various other treatment options for their hypertension.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Vecamyl is FDA approved for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.

Rationale/Source

The rationale behind this policy is to ensure that Vecamyl is being utilized for its labeled indication AND that the patient has progressed through standard therapies prior to receiving Vecamyl, which is typically a last line of defense for hypertension. There are various other drugs/mechanisms of action available for use in the treatment of hypertension that are clinically effective and far more economical than Vecamyl.

References

1. Vecamyl [package insert]. Turing Pharmaceuticals. New York, New York. Updated April 2015.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

mecamylamine (Vecamyl[®])

Policy # 00528

Original Effective Date: 01/01/2017

Current Effective Date: 10/12/2020

Policy History

Original Effective Date: 01/01/2017

Current Effective Date: 10/12/2020

09/08/2016 Medical Policy Committee review

09/21/2016 Medical Policy Implementation Committee approval. New policy.

09/07/2017 Medical Policy Committee review

09/20/2017 Medical Policy Implementation Committee approval. No change to coverage.

09/06/2018 Medical Policy Committee review

09/19/2018 Medical Policy Implementation Committee approval. No change to coverage.

09/05/2019 Medical Policy Committee review

09/11/2019 Medical Policy Implementation Committee approval. No change to coverage.

09/03/2020 Medical Policy Committee review

09/09/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 09/2021

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

mecamylamine (Vecamyl®)

Policy # 00528

Original Effective Date: 01/01/2017

Current Effective Date: 10/12/2020

3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.